INTENSITY THERAPEUTICS, INC. Research and Development Expense
INTENSITY THERAPEUTICS, INC. (INTS) reported Research and Development Expense of $1.83 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- INTENSITY THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $1.83M, a 18.95% increase year-over-year.
- INTENSITY THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $1.20M, a 45.41% decline year-over-year.
- INTENSITY THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $1.50M, a 23.64% decline year-over-year.
- INTENSITY THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $1.55M, a 27.80% decline year-over-year.
- INTENSITY THERAPEUTICS, INC. research and development expense for fiscal 2025 was $6.79M, a 35.36% decline from fiscal 2024.
- INTENSITY THERAPEUTICS, INC. research and development expense for fiscal 2024 was $10.50M, a 119.31% increase from fiscal 2023.
- INTENSITY THERAPEUTICS, INC. research and development expense for fiscal 2023 was $4.79M, a 6.74% decline from fiscal 2022.
- INTENSITY THERAPEUTICS, INC. research and development expense for fiscal 2022 was $5.13M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.83M 10-Q · filed 2026-08-11 | $3.03M 10-Q · filed 2026-08-11 | $4.53M derived: sum of 3 quarters · filed 2026-08-11 | $6.08M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2026-03-31 | $1.20M 10-Q · filed 2026-05-07 | $2.70M derived: sum of 2 quarters · filed 2026-05-07 | $4.25M derived: sum of 3 quarters · filed 2026-05-07 | $5.79M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $3.06M derived: sum of 2 quarters · filed 2026-03-27 | $4.60M derived: sum of 3 quarters · filed 2026-08-11 | $6.79M 10-K · filed 2026-03-27 | |||
| 2025-09-30 | $1.55M 10-Q · filed 2025-11-06 | $3.09M derived: sum of 2 quarters · filed 2026-08-11 | $5.28M 10-Q · filed 2025-11-06 | $7.25M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-06-30 | $1.54M 10-Q · filed 2026-08-11 | $3.73M 10-Q · filed 2026-08-11 | $5.70M derived: sum of 3 quarters · filed 2026-08-11 | $7.85M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-03-31 | $2.19M 10-Q · filed 2026-05-07 | $4.16M derived: sum of 2 quarters · filed 2026-05-07 | $6.31M derived: sum of 3 quarters · filed 2026-05-07 | $9.87M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $4.12M derived: sum of 2 quarters · filed 2026-03-27 | $7.68M derived: sum of 3 quarters · filed 2026-03-27 | $10.50M 10-K · filed 2026-03-27 | |||
| 2024-09-30 | $2.15M 10-Q · filed 2025-11-06 | $5.71M derived: sum of 2 quarters · filed 2025-11-06 | $8.53M 10-Q · filed 2025-11-06 | $10.33M derived: sum of 4 quarters · filed 2025-11-06 | |||
| 2024-06-30 | $3.56M 10-Q · filed 2025-08-07 | $6.38M 10-Q · filed 2025-08-07 | $8.18M derived: sum of 3 quarters · filed 2025-08-07 | $9.53M derived: sum of 4 quarters · filed 2025-08-07 | |||
| 2024-03-31 | $2.81M 10-Q · filed 2025-05-13 | $4.62M derived: sum of 2 quarters · filed 2025-05-13 | $5.97M derived: sum of 3 quarters · filed 2025-05-13 | $6.83M derived: sum of 4 quarters · filed 2025-05-13 | |||
| 2023-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $3.15M derived: sum of 2 quarters · filed 2025-03-13 | $4.01M derived: sum of 3 quarters · filed 2025-03-13 | $4.79M 10-K · filed 2025-03-13 | |||
| 2023-09-30 | $1.35M 10-Q · filed 2024-11-13 | $1.35M 10-Q · filed 2023-11-13 | $2.21M derived: sum of 2 quarters · filed 2024-11-13 | $2.98M 10-Q · filed 2024-11-13 | $2.98M 10-Q · filed 2023-11-13 | $3.88M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $859.00K 10-Q · filed 2024-08-08 | $859.21K 10-Q · filed 2023-08-14 | $1.63M 10-Q · filed 2024-08-08 | $1.63M 10-Q · filed 2023-08-14 | $2.52M derived: sum of 3 quarters · filed 2024-08-08 | $3.68M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $774.00K 10-Q · filed 2024-05-09 | $1.66M derived: sum of 2 quarters · filed 2024-05-09 | $2.83M derived: sum of 3 quarters · filed 2024-05-09 | $4.21M derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | $890.80K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $2.05M derived: sum of 2 quarters · filed 2024-03-14 | $3.44M derived: sum of 3 quarters · filed 2024-03-14 | $5.13M 10-K · filed 2024-03-14 | |||
| 2022-09-30 | $1.16M 10-Q · filed 2023-11-13 | $2.55M derived: sum of 2 quarters · filed 2023-11-13 | $4.24M 10-Q · filed 2023-11-13 | ||||
| 2022-06-30 | $1.39M 10-Q · filed 2023-08-14 | $3.08M 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |